In part 4 of this Exclusive Interview, Dr. Mary Loeken talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, CA about reducing the risk of birth defects in women with diabetes.

In part 5 of this Exclusive Interview, Dr. Mary Loeken talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, CA about finding ways to study the effects of diabetes drugs on pregnant women.

In part 6 of this Exclusive Interview, Dr. Mary Loeken talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, CA about the research to reduce the risk of birth defects and other potential risks of diabetes.

In part 7 of this Exclusive Interview, Dr. Mary Loeken talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, CA about the advances in research to decrease the risk of birth defects in pregnant women with diabetes.

In part 8, the conclusion of this Exclusive Interview, Dr. Mary Loeken talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, CA about her dreams for future accomplishments in her research. Mary Loeken, PhD is an Associate Professor of Medicine at Harvard Medical School …

Almost 100 years ago, researchers figured out that the failure of the beta cells of the pancreas led to diabetes. It was more than 25 years later when we first made the distinction between type 1 and type 2 diabetes. In the next 15 years we discovered a medicine that …

As a CDE who specializes in obesity medicine and diabetes, I hear many patients with either or both diagnoses say they are ready to get a “new start.” It’s not unusual for patients to change the medications, or even stop the medications, we have agreed on for them, and their numbers go up.

In part 2 of this Exclusive Interview, Dr. Ray Kausik talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 convention in San Diego, CA about the impact of PCSK9 inhibitor on cholesterol.

In this week's Homerun Slides, defining the extent of beta cell loss.

Glucose-lowering agents: Metformin is a biguanide that has been used worldwide for more than 50 years for the treatment of T2DM although its exact mechanism of action remains incompletely understood. It decreases hepatic glucose production and improves insulin sensitivity at the level of the liver, and to a lesser extent, muscle. Metformin has been reported to reduce plasma aminotransferase levels in patients with NAFLD. Early small studies suggested that metformin improved hepatic steatosis, necro-inflammation and/or fibrosis in patients with NASH, but not in more recent and better controlled clinical trials.